

# Hemal Mehta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2685208/publications.pdf>

Version: 2024-02-01

16  
papers

530  
citations

1163117

8  
h-index

940533

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

729  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. <i>Progress in Retinal and Eye Research</i> , 2018, 65, 127-146.	15.5	205
2	Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. <i>Eye</i> , 2020, 34, 1-51.	2.1	104
3	Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). <i>Ophthalmology</i> , 2016, 123, 1399-1401.	5.2	68
4	Ranibizumab or Aflibercept for Diabetic Macular Edema. <i>Ophthalmology</i> , 2020, 127, 608-615.	5.2	42
5	Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial. <i>British Journal of Ophthalmology</i> , 2016, 100, 1000-1004.	3.9	32
6	The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial. <i>Ophthalmology Retina</i> , 2018, 2, 231-234.	2.4	13
7	Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2018, 102, 479-482.	3.9	12
8	Changes in real-world treatment patterns for diabetic macular oedema from 2009 to 2019 and 5-year outcomes: Data from the Fight Retinal Blindness! Registry. <i>Clinical and Experimental Ophthalmology</i> , 2020, 48, 802-812.	2.6	10
9	Macular Telangiectasia Type 2 Without Clinically Detectable Vasculopathy. <i>JAMA Ophthalmology</i> , 2015, 133, 951.	2.5	9
10	Outcomes of cataract surgery in eyes with diabetic macular oedema: Data from the Fight Retinal Blindness! Registry. <i>Clinical and Experimental Ophthalmology</i> , 2020, 48, 462-469.	2.6	9
11	12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry. <i>Acta Ophthalmologica</i> , 2022, 100, .	1.1	7
12	Dexamethasone implant for the treatment of persistent diabetic macular oedema despite long-term treatment with bevacizumab. <i>Clinical and Experimental Ophthalmology</i> , 2019, 47, 287-289.	2.6	5
13	Management of Cataract in Patients with Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , 2021, 10, 2538.	2.4	4
14	The ocular adverse effects of oral drugs. <i>Australian Prescriber</i> , 2021, 44, 129-136.	1.0	4
15	Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry. <i>Acta Ophthalmologica</i> , 2022, 100, 285-294.	1.1	3
16	Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion. <i>Eye</i> , 2023, 37, 1145-1154.	2.1	3